Chronic Pelvic Pain, Fibromyalgia, Interstitial Cystitis, Irritable Bowel Syndrome, Post Traumatic Stress Disorder
Conditions
Keywords
vulvodynia, painful bladder syndrome, myofascial pain syndrome, pelvic floor tension myalgia
Brief summary
We will rigorously test whether modulation of the motor cortex by transcranial direct current stimulation (tDCS) is an effective treatment for patients with chronic pelvic pain through the following specific aims: A) The primary aim of this study is to determine whether transcranial direct current stimulation applied to the motor cortex in patients with chronic pelvic pain induces a significant decrease in the pain or symptoms as compared with sham tDCS. We will also measure changes in the clinical symptom scores of multiple pelvic organs, drug intake (narcotic), anxiety, depression, traumatic stress, as well as overall improvement in the quality of life to assess the effects of this treatment. B) Determine the duration of the clinical effects of tDCS. We will therefore compare the amelioration of pain and related symptoms between active and sham tDCS for one year following treatment. C) Determine whether tDCS changes the threshold for pain detection as compared with sham tDCS. Patients with chronic pelvic pain have a lower threshold for pain as compared to healthy subjects and we hypothesized that this threshold will increase after stimulation with tDCS. D) Finally, we will examine whether 5 days of tDCS treatment is safe for use in chronic pelvic pain patients. Safety will be assessed through neuropsychological tests and adverse event reporting.
Interventions
PROCEDUREtDCS
During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
Sponsors
Summa Health System
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must be females between 18 and 55 years of age. * Subjects must have a current VAS for pelvic pain of 5 or more.
Exclusion criteria
* Known pelvic malignancy. * Patients with major depression with suicidal risk as clinically defined. * Patients with other known, uncontrolled neuropsychiatric disorders. * Abnormal neurological examination other than as signs of the condition studied in the present protocol. * Contraindication to tDCS: * A history of unmanaged substance abuse or dependence within the last 6 months. * A history of previous treatment with tDCS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient Global Assessment (PGA): | 2 weeks |
| Visual analog scale (VAS) for pain: | 2 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Interstitial cystitis symptom index: | 2 weeks |
Countries
United States
Outcome results
None listed